Profile data is unavailable for this security.
About the company
Aditxt, Inc. is a social innovation platform dedicated to accelerating promising health innovations. It develops and commercializes technologies with a focus on monitoring and modulating the immune system. Its portfolio includes Adimune, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; Adivir, Inc., focused on identifying, developing, and commercializing new ways to treat infectious diseases, and Pearsanta, Inc., offering personalized lab testing, backed by CLIA-certified and CAP-accredited monitoring center. Adimune, Inc's immune modulation product candidate, ADI-100, is based on the Apoptotic DNA Immunotherapy platform technology, utilizes a novel approach that mimics the way bodies naturally induce tolerance to own tissues. It also offers electroencephalography (EEG) brain monitoring technologies and devices, including NeuroCap and NeuroEEG for telehealth and tele-neurology applications.
- Revenue in USD (TTM)5.95k
- Net income in USD-42.24m
- Incorporated2017
- Employees26.00
- LocationAditxt Inc737 N. Fifth Street, Suite 200RICHMOND 23219United StatesUSA
- Phone+1 (909) 488-0844
- Fax+1 (302) 674-2100
- Websitehttps://aditxt.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMGC Holdings Inc | 285.95k | -4.48m | 696.95k | 2.00 | -- | 0.03 | -- | 2.44 | -57.57 | -129.01 | 3.93 | 45.64 | 0.0219 | 0.373 | 1.98 | 142,975.00 | -34.29 | -- | -48.32 | -- | 27.29 | -- | -1,567.42 | -- | 1.77 | -32.16 | 0.2734 | -- | -- | -- | -142.45 | -- | -- | -- |
| Hepion Pharmaceuticals Inc | 0.00 | -9.17m | 697.22k | 22.00 | -- | 0.4279 | -- | -- | -13.39 | -13.39 | 0.00 | 0.2861 | 0.00 | -- | -- | -- | -245.96 | -65.13 | -417.51 | -73.82 | -- | -- | -- | -- | -- | -5.25 | 0.0606 | -- | -- | -- | 73.04 | -- | -- | -- |
| CeCors Inc | -100.00bn | -100.00bn | 763.78k | 6.00 | -- | -- | -- | -- | -- | -- | -- | -0.0163 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 22.70 | -- | -- | -- |
| Protagenic Therapeutics Inc | -100.00bn | -100.00bn | 773.95k | 1.00 | -- | -- | -- | -- | -- | -- | -- | -2.43 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.2945 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -49.19m | 835.39k | 8.00 | -- | -- | -- | -- | -175.56 | -175.56 | 0.00 | -3.04 | 0.00 | -- | -- | 0.00 | -282.75 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -52.12 | -- | -- | -- |
| Lipella Pharmaceuticals Inc | 389.79k | -5.33m | 887.20k | 5.00 | -- | 0.5964 | -- | 2.28 | -2.41 | -2.41 | 0.1286 | 0.3219 | 0.1729 | -- | 25.08 | 77,958.00 | -236.36 | -101.93 | -336.65 | -125.09 | -- | -- | -1,367.34 | -592.18 | -- | -- | 0.00 | -- | 19.29 | -5.04 | -8.60 | -- | -- | -- |
| Emmaus Life Sciences Inc | 11.89m | -7.29m | 983.53k | 34.00 | -- | -- | -- | 0.0827 | -0.1141 | -0.1141 | 0.1862 | -0.9315 | 0.4945 | 0.6596 | 3.13 | 349,794.10 | -30.31 | -14.68 | -- | -211.99 | 92.17 | 90.14 | -61.29 | -32.65 | 0.0557 | -0.1912 | -- | -- | -43.73 | -6.05 | -72.86 | -- | -27.52 | -- |
| VG Life Sciences Inc | 0.00 | -4.30m | 1.05m | 7.00 | -- | -- | -- | -- | -0.0721 | -0.0721 | 0.00 | -0.0491 | 0.00 | -- | -- | -- | -384.41 | -294.08 | -- | -- | -- | -- | -- | -587,591.90 | -- | -1.70 | -- | -- | -- | -- | 16.58 | -- | -- | -- |
| Herborium Group Inc | 340.33k | -318.65k | 1.09m | 2.00 | -- | -- | -- | 3.21 | -0.3492 | -0.3492 | 0.3672 | -1.16 | 2.32 | 3.89 | 25.94 | -- | -216.97 | -490.56 | -- | -- | 58.31 | 56.36 | -93.63 | -186.81 | 0.0331 | -39.14 | -- | -- | 19.45 | -18.15 | 120.44 | -- | -- | -- |
| Aditxt Inc | 5.95k | -42.24m | 1.10m | 26.00 | -- | -- | -- | 184.23 | -13,234.74 | -13,234.74 | 0.3444 | -151.86 | 0.0003 | 1.54 | 0.0304 | 228.85 | -207.03 | -148.78 | -- | -279.11 | -1,134.96 | -- | -724,419.70 | -8,283.15 | 0.02 | -12.48 | -- | -- | -79.23 | -- | -23.40 | -- | -- | -- |
| Halberd Corp | 281.24k | 25.34k | 1.13m | 3.00 | 0.6897 | -- | 44.61 | 4.02 | 0.0023 | 0.0023 | 0.0018 | -0.0002 | 0.1449 | 0.0303 | 2.52 | -- | 1.31 | -- | 4.58 | -- | 50.00 | -- | 9.01 | -- | 0.2661 | 1.35 | 1.02 | -- | 271.52 | -- | -60.11 | -- | -- | -- |
| Pharmagreen Biotech Inc | 3.01k | -226.26k | 1.26m | 0.00 | -- | -- | 2.28 | 418.91 | -0.0003 | -0.0003 | 0.00 | -0.0035 | 0.0286 | 0.2026 | 0.0669 | -- | -214.92 | -709.50 | -- | -- | 44.85 | -- | -7,518.27 | -147,637.60 | 0.0375 | -- | -- | -- | 13.67 | -- | -76.59 | -- | -- | -- |
| Exousia Pro Inc | 0.00 | -854.02k | 1.35m | 0.00 | -- | -- | -- | -- | -0.0642 | -0.0642 | 0.00 | -0.0318 | 0.00 | -- | -- | -- | -1,313,877.00 | -- | -- | -- | -- | -- | -- | -- | -- | -1,816.06 | -- | -- | -- | -- | -248.31 | -- | -- | -- |
| International Stem Cell Corp | 9.39m | -149.00k | 1.40m | 32.00 | -- | -- | 8.70 | 0.1492 | -0.0187 | -0.0187 | 1.17 | 0.0655 | 1.80 | 2.66 | 11.08 | 293,468.80 | -1.13 | -16.11 | -10.84 | -52.88 | 57.86 | 59.53 | -0.6283 | -10.91 | 0.4604 | 0.6258 | 0.8632 | -- | 16.64 | -0.8308 | -59.54 | -- | -19.12 | -- |
Data as of Feb 13 2026. Currency figures normalised to Aditxt Inc's reporting currency: US Dollar USD
7.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HRT Financial LPas of 31 Dec 2025 | 15.90k | 2.84% |
| Jane Street Capital LLCas of 31 Dec 2025 | 12.84k | 2.30% |
| Flow Traders U.S. LLCas of 31 Dec 2025 | 12.45k | 2.23% |
| UBS Securities LLCas of 31 Dec 2025 | 620.00 | 0.11% |
| Virtu Americas LLCas of 30 Sep 2025 | 144.00 | 0.03% |
| Two Sigma Securities LLCas of 30 Sep 2025 | 97.00 | 0.02% |
| Tower Research Capital LLCas of 30 Sep 2025 | 40.00 | 0.01% |
| Group One Trading LLCas of 31 Dec 2025 | 2.00 | 0.00% |
| IFP Advisors LLCas of 31 Dec 2025 | 2.00 | 0.00% |
| Danske Bank A/S (Investment Management)as of 31 Dec 2025 | 2.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
